AB
GLUE icon

Amalgamated Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Amalgamated Bank’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,465
Closed -$23K – 2118
2025
Q4 		$23K Buy
1,465
+40
+3% +$539 ﹤0.01% 2053
2025
Q3 		$11K Hold
1,425
– – ﹤0.01% 2420
2025
Q2 		$6K Hold
1,425
– – ﹤0.01% 2655
2025
Q1 		$7K Buy
1,425
+430
+43% +$2.64K ﹤0.01% 2523
2024
Q4 		$7K Hold
995
– – ﹤0.01% 2593
2024
Q3 		$5K Hold
995
– – ﹤0.01% 2752
2024
Q2 		$4K Hold
995
– – ﹤0.01% 2850
2024
Q1 		$7K Sell
995
-1,738
-64% -$10.3K ﹤0.01% 2582
2023
Q4 		$15K Sell
2,733
-296
-10% -$1.16K ﹤0.01% 2763
2023
Q3 		$15K Hold
3,029
– – ﹤0.01% 2780
2023
Q2 		$21K Hold
3,029
– – ﹤0.01% 2707
2023
Q1 		$24K Sell
3,029
-602
-17% -$4.19K ﹤0.01% 2577
2022
Q4 		$28K Hold
3,631
– – ﹤0.01% 2646
2022
Q3 		$30K Hold
3,631
– – ﹤0.01% 2672
2022
Q2 		$35K Buy
3,631
+799
+28% +$8.03K ﹤0.01% 2644
2022
Q1 		$40K Buy
+2,832
New +$39.3K ﹤0.01% 2575

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Amalgamated Bank's GLUE Position: Q1 2026 in Review

Amalgamated Bank sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 1,465 shares — an estimated $23K sold.

Amalgamated Bank first reported a position in GLUE in Q1 2022 and held it in 16 quarters. The position peaked at $40K in Q1 2022. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Amalgamated Bank reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,465 Monte Rosa Therapeutics shares in Q1 2026, an estimated $23K.
  • Amalgamated Bank first reported a position in Monte Rosa Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Monte Rosa Therapeutics position peaked at $40K in Q1 2022.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.